Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity - PubMed (original) (raw)
Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity
I Bursuker et al. J Exp Med. 1984.
Abstract
This study shows that surgical removal of the meth A fibrosarcoma from its semisyngeneic host fails to result in postexcision immunity to growth of a tumor implant unless the host already has acquired a mechanism of concomitant immunity to growth of an implant. Therefore, tumor excision does not cause immunity to be generated but preserves a mechanism of concomitant immunity that already exists and which otherwise would eventually undergo down-regulation under the influence of suppressor T cells. Removal of the tumor after it has grown large enough to cause the T cell-mediated suppression of concomitant immunity does not result in the reemergence of immunity. Instead, the host remains unable to generate concomitant immunity to a second tumor for a long period of time and retains, for at least 31 d, suppressor T cells able to passively transfer suppression to appropriate recipients. Like the suppressor T cells responsible for active suppression of concomitant immunity, the suppressor T cells responsible for "memory" suppression are of the Ly-1+2- phenotype. The results indicate that progressive tumor growth results in a state of immunological tolerance of tumor-specific, transplantation antigens that can persist in the apparent absence of tumor antigens.
Similar articles
Cited by
- Capturing the dynamics of microbial interactions through individual-specific networks.
Yousefi B, Melograna F, Galazzo G, van Best N, Mommers M, Penders J, Schwikowski B, Van Steen K. Yousefi B, et al. Front Microbiol. 2023 May 15;14:1170391. doi: 10.3389/fmicb.2023.1170391. eCollection 2023. Front Microbiol. 2023. PMID: 37256048 Free PMC article. - The potential of regulatory T cell-based therapies for alopecia areata.
Wan S, Xu W, Xie B, Guan C, Song X. Wan S, et al. Front Immunol. 2023 May 2;14:1111547. doi: 10.3389/fimmu.2023.1111547. eCollection 2023. Front Immunol. 2023. PMID: 37205097 Free PMC article. Review. - Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help.
Medler TR, Kramer G, Bambina S, Gunderson AJ, Alice A, Blair T, Zebertavage L, Duhen T, Duhen R, Young K, Crittenden MR, Gough MJ. Medler TR, et al. Sci Rep. 2023 Apr 18;13(1):6277. doi: 10.1038/s41598-023-33508-1. Sci Rep. 2023. PMID: 37072485 Free PMC article. - Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.
Ding Y, Wang Z, Zhou F, Chen C, Qin Y. Ding Y, et al. Front Oncol. 2022 Sep 30;12:987302. doi: 10.3389/fonc.2022.987302. eCollection 2022. Front Oncol. 2022. PMID: 36248998 Free PMC article. Review. - ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control.
Blair T, Baird J, Bambina S, Kramer G, Gostissa M, Harvey CJ, Gough MJ, Crittenden MR. Blair T, et al. Sci Rep. 2022 Sep 2;12(1):14954. doi: 10.1038/s41598-022-19256-8. Sci Rep. 2022. PMID: 36056093 Free PMC article.
References
- J Exp Med. 1981 Oct 1;154(4):1033-42 - PubMed
- Adv Cancer Res. 1983;39:71-120 - PubMed
- Cancer Res. 1964 Dec;24:1994-6 - PubMed
- Annu Rev Med. 1964;15:167-86 - PubMed
- Immunol Rev. 1979;46:3-26 - PubMed